JPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE